Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 32: 361-363, 1986;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lockitch, G.
Right arrow Articles by Campbell, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lockitch, G.
Right arrow Articles by Campbell, D. J.

Clinical Chemistry, Vol 32, 361-363, Copyright © 1986 by American Association for Clinical Chemistry

Prediction of fetal lung maturity by use of the Lumadex-FSI test

G Lockitch, BK Wittmann, BE Snow and DJ Campbell

We analyzed amniotic fluid from 91 pregnancies (estimated gestational age range 31 to 41 weeks), using the Lumadex-FSI Fetal Lung Maturity test (Beckman Instruments), and also determining phosphatidylglycerol content, the lecithin/sphingomyelin ratio, and foam stability index by the "shake test," and compared results with newborn outcome. Five of 64 babies born within 72 h of testing developed hyaline membrane disease. Except for the lecithin/sphingomyelin ratio, the predictive value of a negative test was 100% but that of a positive test was less than 50%. Use of all four tests did not offer diagnostic advantage over the use of Lumadex-FSI alone. For the laboratory that infrequently assesses fetal lung maturity, we believe the sealed cassette format of the Lumadex-FSI will permit better quality assurance than the shake test. The Lumadex-FSI test is intended to provide a graded estimate of positive risk for hyaline membrane disease, but more data from different centers and patient populations are needed to establish reliable predictive values.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
E. R. Ashwood
Standards of laboratory practice: evaluation of fetal lung maturity
Clin. Chem., January 1, 1997; 43(1): 211 - 214.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by the American Association for Clinical Chemistry.